DK2646011T3 - Fremgangsmåder til reduktion af overspisning eller tvangsspisning - Google Patents

Fremgangsmåder til reduktion af overspisning eller tvangsspisning

Info

Publication number
DK2646011T3
DK2646011T3 DK11844637.6T DK11844637T DK2646011T3 DK 2646011 T3 DK2646011 T3 DK 2646011T3 DK 11844637 T DK11844637 T DK 11844637T DK 2646011 T3 DK2646011 T3 DK 2646011T3
Authority
DK
Denmark
Prior art keywords
eating
forcing
methods
reducing over
reducing
Prior art date
Application number
DK11844637.6T
Other languages
Danish (da)
English (en)
Inventor
Eduardo Dunayevich
Susan Mcelroy
Ron Landbloom
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2646011(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Application granted granted Critical
Publication of DK2646011T3 publication Critical patent/DK2646011T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
DK11844637.6T 2010-12-03 2011-12-02 Fremgangsmåder til reduktion af overspisning eller tvangsspisning DK2646011T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41935410P 2010-12-03 2010-12-03
PCT/US2011/063170 WO2012075453A1 (en) 2010-12-03 2011-12-02 Methods for reducing binge or compulsive eating

Publications (1)

Publication Number Publication Date
DK2646011T3 true DK2646011T3 (da) 2017-11-20

Family

ID=46172302

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11844637.6T DK2646011T3 (da) 2010-12-03 2011-12-02 Fremgangsmåder til reduktion af overspisning eller tvangsspisning

Country Status (27)

Country Link
US (2) US20130252995A1 (enExample)
EP (1) EP2646011B1 (enExample)
JP (1) JP2014508717A (enExample)
KR (1) KR20140035319A (enExample)
CN (1) CN103298462A (enExample)
AR (2) AR084093A1 (enExample)
AU (3) AU2011336298B2 (enExample)
BR (1) BR112013015957B1 (enExample)
CA (1) CA2819003A1 (enExample)
CL (1) CL2013001565A1 (enExample)
CY (1) CY1119560T1 (enExample)
DK (1) DK2646011T3 (enExample)
ES (1) ES2647232T3 (enExample)
HR (1) HRP20171678T1 (enExample)
HU (1) HUE034641T2 (enExample)
IL (1) IL226483A0 (enExample)
LT (1) LT2646011T (enExample)
MX (1) MX350304B (enExample)
NO (1) NO2646011T3 (enExample)
PL (1) PL2646011T3 (enExample)
PT (1) PT2646011T (enExample)
RS (1) RS56548B1 (enExample)
RU (1) RU2620913C2 (enExample)
SI (1) SI2646011T1 (enExample)
SM (1) SMT201700537T1 (enExample)
TW (2) TWI536986B (enExample)
WO (1) WO2012075453A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197250C2 (ru) * 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US20100317572A1 (en) * 2007-12-20 2010-12-16 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
KR102385359B1 (ko) * 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료

Also Published As

Publication number Publication date
US20130252995A1 (en) 2013-09-26
WO2012075453A1 (en) 2012-06-07
BR112013015957B1 (pt) 2021-07-20
AU2017202793A1 (en) 2017-05-18
NO2646011T3 (enExample) 2018-01-13
AU2011336298A1 (en) 2013-07-11
PT2646011T (pt) 2017-11-17
CN103298462A (zh) 2013-09-11
CA2819003A1 (en) 2012-06-07
RU2620913C2 (ru) 2017-05-30
HUE034641T2 (en) 2018-02-28
PL2646011T3 (pl) 2018-01-31
KR20140035319A (ko) 2014-03-21
BR112013015957A2 (pt) 2019-10-29
LT2646011T (lt) 2017-11-10
JP2014508717A (ja) 2014-04-10
US20210283126A1 (en) 2021-09-16
SMT201700537T1 (it) 2018-01-11
AU2018203921A1 (en) 2018-06-21
EP2646011B1 (en) 2017-08-16
RS56548B1 (sr) 2018-02-28
HRP20171678T1 (hr) 2017-12-15
IL226483A0 (en) 2013-07-31
TWI536986B (zh) 2016-06-11
AU2017202793B2 (en) 2018-03-08
TW201228659A (en) 2012-07-16
CL2013001565A1 (es) 2014-04-04
EP2646011A1 (en) 2013-10-09
MX2013006070A (es) 2013-07-29
RU2013127420A (ru) 2015-01-10
CY1119560T1 (el) 2018-03-07
MX350304B (es) 2017-09-04
SI2646011T1 (en) 2018-01-31
TW201735912A (zh) 2017-10-16
AR124497A2 (es) 2023-04-05
AU2011336298B2 (en) 2017-03-02
ES2647232T3 (es) 2017-12-20
AR084093A1 (es) 2013-04-17
EP2646011A4 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
IL225867B (en) Coelenterazine substrates
HRP20160862T8 (hr) Sklop posude i pridruženi postupak
BR112012015988A2 (pt) método
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK3372280T3 (da) Forbedringer af eller vedrørende synsevnen
BR112014010450A2 (pt) composição e método
EP2589737A4 (en) WINDOW REGULATOR
DK2622532T3 (da) Fremgangsmåde til kollaborativ beregning
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
CO6980141A1 (es) Compuestos y composiciones de poliglicerilo catónicos
DK2555704T3 (da) Visning af hæmostatiske parametre
PL3299356T3 (pl) Sposób wytwarzania pleuromutylin
FR2962044B1 (fr) Emulsion lacrymimetique
IL225346A0 (en) Serum preparation
PT2736340T (pt) Biocontrolo de nemátodos
DK2782565T3 (da) Anvendelse af aryl- og hetarylcarboxamider som endoparasiticider
BR112013009024A2 (pt) método
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
BR112012023743A2 (pt) formas polimórficas st-246 e métodos de preparação
BR112012023891A2 (pt) método
ITTO20110268A1 (it) Composizione di maquillage.
DK3067219T3 (da) Fremgangsmåde til fremstilling af paneler
BR112014010860A2 (pt) composição e método
BR112012029669A2 (pt) composição e método
CU24148B1 (es) Intermedios de agomelatina y método de preparación de éstos